Citation

Li LS, Zhou Y, Murphy DE, Stankovic N, Zhao J, Dragovich PS, Bertolini T, Sun Z, Ayida B, Tran CV, Ruebsam F, Webber SE, Shah AM, Tsan M, Showalter RE, Patel R, Lebrun LA, Bartkowski DM, Nolan TG, Norris DA, Kamran R, Brooks J, Sergeeva MV, Kirkovsky L, Zhao Q, Kissinger CR.: Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments. Bioorg Med Chem Lett, Volume 18 (11), 2008

Authors

Ayida B, Bartkowski DM, Bertolini T, Brooks J, Dragovich PS, Kamran R, Kirkovsky L, Kissinger CR., Lebrun LA, Li LS, Murphy DE, Nolan TG, Norris DA, Patel R, Ruebsam F, Sergeeva MV, Shah AM, Showalter RE, Stankovic N, Sun Z, Tran CV, Tsan M, Webber SE, Zhao J, Zhao Q, Zhou Y

Journal

Bioorg Med Chem Lett

Year

2008

DOI

10.1016/j.bmcl.2008.02.072

PubMed

18457949

Machine-readable

REST APIRDF